Mahmoud H H, Wang W C, Murphy S B
Department of Hematology-Oncology, St. Jude Children's Research Hospital, Memphis, TN 38101.
Blood. 1991 Feb 15;77(4):721-5.
Prompted by evidence that Langerhans cell histiocytosis (LCH) is a nonmalignant disorder of immune regulation, we used cyclosporine (12 mg/kg/d orally) to treat three young children with advanced multisystem LCH. All three patients had partial responses to cyclosporine within 2 months of therapy, as evidenced by complete resolution of organ dysfunction and regression of the majority of lesions. Complete responses were attained by adding relatively nontoxic chemotherapy (ie, prednisone and vinblastine). Toxicity from cyclosporine comprised mild and reversible elevations of the serum creatinine and blood urea nitrogen. These results indicate that further evaluation of cyclosporine for the treatment of patients with advanced LCH is warranted.
鉴于有证据表明朗格汉斯细胞组织细胞增多症（LCH）是一种免疫调节的非恶性疾病，我们使用环孢素（口服12毫克/千克/天）治疗了三名患有晚期多系统LCH的幼儿。所有三名患者在治疗的2个月内对环孢素均有部分反应，表现为器官功能障碍完全消退以及大多数病变缩小。通过添加相对无毒的化疗药物（即泼尼松和长春碱）实现了完全缓解。环孢素的毒性表现为血清肌酐和血尿素氮轻度且可逆的升高。这些结果表明，有必要对环孢素治疗晚期LCH患者进行进一步评估。
